NCT05104775View on ClinicalTrials.gov

A Study of GNC-035, a Tetra-specific Antibody, in Participants With Relapsed/Refractory Hematologic Malignancy

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

February 9, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Hematologic Malignancies
Interventions
DRUG

GNC-035

Administration by intravenous infusion.

Trial Locations (7)

200025

Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai

Unknown

Guangzhou First People's Hospital, Guangzhou

Affiliated Hospital of Guizhou Medical University, Guiyang

The Fourth Hospital of Hebei Medical University, Shijiazhuang

Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan

Shengjing Hospital of China Medical University, Shenyang

The Second People's Hospital of Yibin, Yibin

All Listed Sponsors
collaborator

SystImmune Inc.

INDUSTRY

lead

Sichuan Baili Pharmaceutical Co., Ltd.

INDUSTRY

NCT05104775 - A Study of GNC-035, a Tetra-specific Antibody, in Participants With Relapsed/Refractory Hematologic Malignancy | Biotech Hunter | Biotech Hunter